{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T03:03:20Z","timestamp":1740107000772,"version":"3.37.3"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2017,10,24]],"date-time":"2017-10-24T00:00:00Z","timestamp":1508803200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100008373","name":"Takeda Pharmaceutical Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008373","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2018,3]]},"DOI":"10.1007\/s00520-017-3914-2","type":"journal-article","created":{"date-parts":[[2017,10,23]],"date-time":"2017-10-23T21:31:35Z","timestamp":1508794295000},"page":"933-945","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Comparison of quality of life between 2-year and 3-or-more-year administration of leuprorelin acetate every-3-months depot in combination with tamoxifen as adjuvant endocrine treatment in premenopausal patients with endocrine-responsive breast cancer: a randomized controlled trial"],"prefix":"10.1007","volume":"26","author":[{"given":"Yasuo","family":"Ohashi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eiichi","family":"Shiba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroko","family":"Yamashita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junichi","family":"Kurebayashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinzaburo","family":"Noguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hirotaka","family":"Iwase","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michihiro","family":"Yoshida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tsukasa","family":"Fujimoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,10,24]]},"reference":[{"key":"3914_CR1","doi-asserted-by":"crossref","first-page":"689","DOI":"10.3109\/02841869509094050","volume":"34","author":"LJ Fallowfield","year":"1995","unstructured":"Fallowfield LJ (1995) Assessment of quality of life in breast cancer. Acta Oncol 34:689\u2013694","journal-title":"Acta Oncol"},{"key":"3914_CR2","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1016\/j.breast.2005.08.012","volume":"14","author":"L Fallowfield","year":"2005","unstructured":"Fallowfield L (2005) Acceptance of adjuvant therapy and quality of life issues. Breast 14:612\u2013616","journal-title":"Breast"},{"key":"3914_CR3","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1093\/jnci\/95.4.263","volume":"95","author":"PJ Goodwin","year":"2003","unstructured":"Goodwin PJ, Black JT, Bordeleau LJ, Ganz PA (2003) Health-related quality-of-life measurement in randomized clinical trials in breast cancer\u2014taking stock. J Natl Cancer Inst 95:263\u2013281","journal-title":"J Natl Cancer Inst"},{"key":"3914_CR4","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1093\/jnci\/djq508","volume":"103","author":"J Lemieux","year":"2011","unstructured":"Lemieux J, Goodwin PJ, Bordeleau LJ, Lauzier S, Th\u0117berge V (2011) Quality-of-life measurement in randomized clinical trials in breast cancer: an updated systematic review (2001\u20132009). J Natl Cancer Inst 103:178\u2013231","journal-title":"J Natl Cancer Inst"},{"issue":"3 Suppl","key":"3914_CR5","doi-asserted-by":"crossref","first-page":"1056s","DOI":"10.1158\/1078-0432.CCR-05-2185","volume":"12","author":"TJ Whelan","year":"2006","unstructured":"Whelan TJ, Pritchard KI (2006) Managing patients on endocrine therapy: focus on quality-of-life issues. Clin Cancer Res 12(3 Suppl):1056s\u20131060s","journal-title":"Clin Cancer Res"},{"key":"3914_CR6","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/1477-7525-5-24","volume":"5","author":"S Perry","year":"2007","unstructured":"Perry S, Kowalski TL, Chang CH (2007) Quality of life assessment in women with breast cancer: benefits, acceptability and utilization. Health Qual Life Outcomes 5:24","journal-title":"Health Qual Life Outcomes"},{"key":"3914_CR7","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1007\/s10549-010-1236-x","volume":"127","author":"RE Patterson","year":"2011","unstructured":"Patterson RE, Saquib N, Natarajan L, Rock CL, Parker BA, Thomson CA, Pierce JP (2011) Improvement in self-reported physical health predicts longer survival among women with a history of breast cancer. Breast Cancer Res Treat 127:541\u2013547","journal-title":"Breast Cancer Res Treat"},{"key":"3914_CR8","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1093\/jnci\/90.21.1601","volume":"90","author":"A Goldhirsch","year":"1998","unstructured":"Goldhirsch A, Glick JH, Gelber RD, Senn HJ (1998) Meeting highlights: international consensus panel on the treatment of primary breast cancer. J Natl Cancer Inst 90:1601\u20131608","journal-title":"J Natl Cancer Inst"},{"key":"3914_CR9","doi-asserted-by":"crossref","first-page":"4628","DOI":"10.1200\/JCO.2002.05.042","volume":"20","author":"W Jonat","year":"2002","unstructured":"Jonat W, Kaufmann M, Sauerbrei W, Blamey R, Cuzick J, Namer M, Fogelman I, de Haes JC, de Matteis A, Stewart A, Eiermann W, Szakolczai I, Palmer M, Schumacher M, Geberth M, Lisboa B, Zoladex Early Breast Cancer Research Association Study (2002) Goserelin versus cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy in premenopausal patients with node-positive breast cancer: the Zoladex early breast cancer research association study. J Clin Oncol 20:4628\u20134635","journal-title":"J Clin Oncol"},{"key":"3914_CR10","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1016\/S0140-6736(05)66544-0","volume":"365","author":"Early Breast Cancer Trialists\u2019 Collaborative Group (EBCTCG)","year":"2005","unstructured":"Early Breast Cancer Trialists\u2019 Collaborative Group (EBCTCG) (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365:1687\u20131717","journal-title":"Lancet"},{"key":"3914_CR11","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1200\/JCO.2006.08.8534","volume":"25","author":"P Schmid","year":"2007","unstructured":"Schmid P, Untch M, Koss\u00e9 V, Bondar G, Vassiljev L, Tarutinov V, Lehmann U, Maubach L, Meurer J, Wallwiener D, Possinger K (2007) Leuprorelin acetate every-3-months depot versus cyclophosphamide, methotrexate, and fluorouracil as adjuvant treatment in premenopausal patients with node-positive breast cancer: the TABLE study. J Clin Oncol 25:2509\u20132515","journal-title":"J Clin Oncol"},{"key":"3914_CR12","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1200\/JCO.2001.19.2.343","volume":"19","author":"JGM Klijn","year":"2001","unstructured":"Klijn JGM, Blamey RW, Baccardo F, Tominaga T, Duchateau L, Sylvester R (2001) Combined tamoxifen and luteinizing hormone-releasing hormone (LHRH) agonist versus LHRH agonist alone in premenopausal advanced breast cancer: a meta-analysis of 4 randomized trials. J Clin Oncol 19:343\u2013353","journal-title":"J Clin Oncol"},{"key":"3914_CR13","doi-asserted-by":"crossref","first-page":"2206","DOI":"10.1093\/annonc\/mdt303","volume":"24","author":"A Goldhirsch","year":"2013","unstructured":"Goldhirsch A, Winer EP, Coates AS, Gelber RD, Piccart-Gebhart M, Th\u00fcrlimann B, Senn HJ, Panel members (2013) Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2013. Ann Oncol 24:2206\u20132223","journal-title":"Ann Oncol"},{"key":"3914_CR14","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1093\/annonc\/mdp322","volume":"20","author":"A Goldhirsch","year":"2009","unstructured":"Goldhirsch A, Ingle JN, Gelber RD, Coates AS, Th\u00fcrlimann B, Senn HJ, Panel members (2009) Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009. Ann Oncol 20:1319\u20131329","journal-title":"Ann Oncol"},{"key":"3914_CR15","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1093\/annonc\/mdr304","volume":"22","author":"A Goldhirsch","year":"2011","unstructured":"Goldhirsch A, Wood WC, Coates AS, Gelber RD, Th\u00fcrlimann B, Senn HJ, Panel members (2011) Strategies for subtypes\u2014dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2011. Ann Oncol 22:1736\u20131747","journal-title":"Ann Oncol"},{"key":"3914_CR16","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1007\/s12282-015-0593-z","volume":"23","author":"E Shiba","year":"2015","unstructured":"Shiba E, Yamashita H, Kurebayashi J, Noguchi S, Iwase H, Ohashi Y, Sasai K, Fujimoto T (2015) A randomized controlled study evaluating safety and efficacy of leuprorelin acetate every-3-months depot for 2 versus 3 or more years with tamoxifen for 5 years as adjuvant treatment in premenopausal patients with endocrine-responsive breast cancer. Breast Cancer (2016) 23:499\u2013509","journal-title":"Breast Cancer"},{"key":"3914_CR17","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1002\/(SICI)1099-1611(199907\/08)8:4<355::AID-PON401>3.0.CO;2-I","volume":"8","author":"M Kurihara","year":"1999","unstructured":"Kurihara M, Shimizu H, Tsuboi K, Kobayashi K, Murakami M, Eguchi K, Shimozuma K (1999) Development of quality of life questionnaire in Japan: quality of life assessment of cancer patients receiving chemotherapy. Psychooncology 8:355\u2013363","journal-title":"Psychooncology"},{"key":"3914_CR18","unstructured":"The Japanese Breast Cancer Society (2002) Guidelines for quality of life assessment studies of breast cancer patients, Version 1.0. (in Japanese)"},{"key":"3914_CR19","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1023\/A:1006263818115","volume":"55","author":"LJ Fallowfield","year":"1999","unstructured":"Fallowfield LJ, Leaity SK, Howell A, Benson S, Cella D (1999) Assessment of quality of life in women undergoing hormonal therapy for breast cancer: validation of an endocrine symptom subscale for the FACT-B. Breast Cancer Res Treat 55:189\u2013199","journal-title":"Breast Cancer Res Treat"},{"key":"3914_CR20","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1056\/NEJMoa1404037","volume":"371","author":"O Pagani","year":"2014","unstructured":"Pagani O, Regan MM, Walley BA, Fleming GF, Colleoni M, L\u00e1ng I, Gomez HL, Tondini C, Burstein HJ, Perez EA, Ciruelos E, Stearns V, Bonnefoi HR, Martino S, Geyer CE Jr, Pinotti G, Puglisi F, Crivellari D, Ruhstaller T, Winer EP, Rabaglio-Poretti M, Maibach R, Ruepp B, Giobbie-Hurder A, Price KN, Bernhard J, Luo W, Ribi K, Viale G, Coates AS, Gelber RD, Goldhirsch A, Francis PA, TEXT and SOFT Investigators; International Breast Cancer Study Group (2014) Adjuvant exemestane with ovarian suppression in premenopausal breast cancer. N Engl J Med 371:107\u2013118","journal-title":"N Engl J Med"},{"key":"3914_CR21","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1056\/NEJMoa1412379","volume":"372","author":"PA Francis","year":"2015","unstructured":"Francis PA, Regan MM, Fleming GF, L\u00e1ng I, Ciruelos E, Bellet M, Bonnefoi HR, Climent MA, Da Prada GA, Burstein HJ, Martino S, Davidson NE, Geyer CE Jr, Walley BA, Coleman R, Kerbrat P, Buchholz S, Ingle JN, Winer EP, Rabaglio-Poretti M, Maibach R, Ruepp B, Giobbie-Hurder A, Price KN, Colleoni M, Viale G, Coates AS, Goldhirsch A, Gelber RD, SOFT Investigators; International Breast Cancer Study Group (2015) Adjuvant ovarian suppression in premenopausal breast cancer. N Engl J Med 372:436\u2013446","journal-title":"N Engl J Med"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00520-017-3914-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-017-3914-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-017-3914-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,1,25]],"date-time":"2018-01-25T03:20:04Z","timestamp":1516850404000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00520-017-3914-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10,24]]},"references-count":21,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018,3]]}},"alternative-id":["3914"],"URL":"https:\/\/doi.org\/10.1007\/s00520-017-3914-2","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"type":"print","value":"0941-4355"},{"type":"electronic","value":"1433-7339"}],"subject":[],"published":{"date-parts":[[2017,10,24]]}}}